CD8A and neoplasm: To determine the roles of CXCL9 and CXCL10 in T-αFGL2-induced tumor rejection and CD8+ TRM cell formation, αCXCL9 and αCXCL10 antibodies were used to block CXCL9 and CXCL10 in vivo.